TearScience (Morrisville, NC) a clinical-stage medical device company focused on the treatment of chronic evaporative dry eye due to obstructive Meibomian Gland Dysfunction, closed a $44.5M Series C financing. Participants include Essex Woodlands Health Ventures, Investor Growth Capital, General Catalyst, De Novo Ventures, Spray Ventures and Quaker Bio Ventures.

ReVance Therapeutics (Mountain View, CA) a clinical-stage biopharmaceutical company focused on dermatology and aesthetic medicine, closed a $25.6M Series D financing. Particpants have included Essex Woodlands Health Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Bio*One Capital and Pac-Link Venture.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Molecular Partners (Switzerland) a preclinical-stage developing DARPins, a potential new class of protein therapeutics focused on ophthalmology indications, closed a $45M Series B financing. Participants include Essex Woodlands Health Ventures, Index Ventures, Johnson & Johnson Development Corp., BB Biotech Ventures and EndeavourVision.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Entellus Medical (Maple Grove, MN) a commercial-stage medical device company focused on the treatment for chronic sinusitis, closed a $30M Series D financing. Participants include Essex Woodlands Health Ventures, Split Rock Partners and SV Life Sciences.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Accumetircs (San Diego,CA) a commercial-stage diagnostic company focused on VerifyNow® System, a comprehensive suite of tests for the assessment of platelet response to antiplatelet therapies, closed a $16.5M Series E financing. Participants inlcude Arnerich Massena, BBT Fund/Apothecary Capital, Essex Woodlands Health Ventures, Kaiser Permanente Ventures and RiverVest Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming [...]